Navigation Links
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Date:7/23/2014

ated that 2/3 of all MPS II patients will be affected with CNS disease; this translates into a prevalence of around 1,200 patients worldwide.  

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

http://www.shire.com

FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

• Shire's products may not be a commercial success;

• revenues from ADDERALL XR are subject to generic erosion and revenues from INTUNIV will become subject to generic competition starting in December 2014;

• the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations;

• Shire conducts its own manufacturing operations for certain of its Rare Diseases products and is reliant on third party contractors to manufacture other products and to provide goods and services. Some of Shire's products or ingredients are only available from a single approved sourc
'/>"/>

SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult ... wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a ... Office of the Chief Scientist (OCS).  This ... receipt of grant support from the Office of the ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... , , , ... , , SAN DIEGO, CA, August ... a company focused on using proprietary taste receptor-based technologies to discover novel ... a corporate update and reported financial results for the second quarter ended ...
... , , , ... Inc., a biotechnology company developing antiviral therapies, announced today that ... C Virus (HCV) technology from Stanford University. This technology, discovered ... Jeffrey Glenn, M.D., Ph.D., is focused on a variety of ...
... , , SAN DIEGO, Aug. ... scheduled to present at the Canaccord Adams 29th Annual Global Growth ... 2:00 p.m. Eastern Time. , , (Logo: ... these presentations will be accessible on the Company,s website at ...
Cached Biology Technology:SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University 2Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Center researchers have discovered how the brain creates a scent ... in mice, the researchers found that nerve cells in the ... the nose -- do not perceive complex scent mixtures as ... Instead, these nerve cells, or neurons, detect the host of ...
... personalized medicine, Howard Hughes Medical Institute investigator Brian J. ... identify previously unknown genetic mutations that can trigger cancerous ... ?inside acute myeloid leukemia (AML) cells, the researchers have ... on molecular abnormalities that might be vulnerable to specific ...
... oceans, their significance as the most important resource for the ... at the centre of discussion during the seminar 'A new ... 2006) in Munich. The primary focus of the seminar will ... potential benefits for industries and society. Friedhelm Schröder and Wilhelm ...
Cached Biology News:Researchers show how brain decodes complex smells 2New strategy rapidly identifies cancer targets 2New strategy rapidly identifies cancer targets 3A new look at the state of the oceans 2A new look at the state of the oceans 3
...
...
with GlutaMAXIL-glutamine...
... GOAT ANTI-MOUSE IgG+IgA+IgM (H+L) ... with highly purified horseradish ... antibody has been absorbed ... fetal bovine, horse, goat, ...
Biology Products: